Gastric and Duodenal Mucosal Healing With Risankizumab in Upper Gastrointestinal Crohn's Disease.

There are very limited data on the efficacy of medical therapies for upper gastrointestinal Crohn's disease (CD), and no data exist for the efficacy of IL-23 p19 inhibition on upper gastrointestinal CD. We present the case of a 21-year-old man with severe gastric and duodenal CD, who demonstrated complete clinical and endoscopic response to risankizumab after 28 weeks of therapy.